SCL Science Inc.

A246960

KR7246960009

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
8,670 ^KRW	-3.34%		+5.73%	-2.25%

Feb. 07	H2U Corp. announced that it has received KRW 1.29506497 billion in funding from InnoTherapy, Inc.	CI
2023	H2U Corp. announced that it has received KRW 1.2171 billion in funding from InnoTherapy, Inc.	CI

SCL Healthcare Co., Ltd. completed the acquisition of 22.97% stake in InnoTherapy, Inc. from Lee, Moon Soo.

December 27, 2022

SCL Healthcare Co., Ltd. agreed to acquire 22.97% stake in InnoTherapy, Inc. (KOSDAQ:A246960) from Lee, Moon Soo for KRW 21.8 billion on November 18, 2022. The offer per share is KRW 17,500. Transaction is expected to be closed on December 30, 2022.

SCL Healthcare Co., Ltd. completed the acquisition of 22.97% stake in InnoTherapy, Inc. (KOSDAQ:A246960) from Lee, Moon Soo on December 28, 2022. SCL Healthcare funded the acquisition with its own funds.

Latest news about SCL Science Inc.

H2U Corp. announced that it has received KRW 1.29506497 billion in funding from InnoTherapy, Inc.	Feb. 06	CI
H2U Corp. announced that it has received KRW 1.2171 billion in funding from InnoTherapy, Inc.	Nov. 29	CI
InnoTherapy, Inc. announced that it has received KRW 5.9999961 billion in funding from Scl Holdings and another investor	Nov. 16	CI
Health to U Corporation announced that it has received funding from InnoTherapy, Inc.	Nov. 08	CI
H2U Corp. announced that it expects to receive KRW 1.2171 billion in funding from InnoTherapy, Inc.	Nov. 07	CI
InnoTherapy, Inc. announced that it expects to receive KRW 5.9999961 billion in funding	23-10-24	CI
PhAST Corp. announced that it has received KRW 1.30609774 billion in funding from InnoTherapy, Inc.	23-07-06	CI
Lee Moon Su completed the acquisition of a 98.04% stake in NVC 2019 Bio Health Care Investment Association from InnoTherapy, Inc.	23-06-29	CI
Lee Moon Su agreed to acquire 98.039216% stake in NVC 2019 Bio Health Care Investment Association from InnoTherapy, Inc. for approximately KRW5 billion.	23-06-25	CI
PhAST Corp. announced that it expects to receive KRW 1.30609774 billion in funding from InnoTherapy, Inc.	23-06-08	CI
InnoTherapy, Inc. announced that it has received KRW 4.999995 billion in funding from SCL Healthcare Co., Ltd., Seoul Clinical Laboratories	23-03-22	CI
InnoTherapy, Inc. announced that it expects to receive KRW 4.999995 billion in funding from SCL Healthcare Co., Ltd., Seoul Clinical Laboratories	23-03-12	CI
SCL Healthcare Co., Ltd. completed the acquisition of 22.97% stake in InnoTherapy, Inc. from Lee, Moon Soo.	22-12-27	CI
SCL Healthcare Co., Ltd. agreed to acquire 22.97% stake in InnoTherapy, Inc. from Lee, Moon Soo for KRW 21.8 billion.	22-11-17	CI
InnoTherapy, Inc. announced that it has received KRW 14.999868397 billion in funding from a group of investors	21-04-08	CI
InnoTherapy, Inc. announced that it expects to receive KRW 7.5 billion in funding from Samsung Securities Co. Ltd., Investment Arm, KB Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, His-Story Investment Co.,Ltd., Shinhan Bank, Investment Arm, Shinhan Bank, Investment Arm, and Pureun Mutual Savings Bank Co., Ltd and another investor	21-03-31	CI
InnoTherapy, Inc. cancelled the acquisition of 98.04% stake in NVC 2019 Bio Health Care Investment Association.	20-10-14	CI
InnoTherapy, Inc. agreed to acquire 98.04% stake in NVC 2019 Bio Health Care Investment Association for KRW 5 billion.	19-10-14	CI
NVC Partners announced that it has received KRW 1.1 billion in funding from InnoTherapy, Inc.	19-06-30	CI
InnoTherapy, Inc. has completed an IPO in the amount of KRW 9 billion.	19-01-29	CI
InnoTherapy, Inc. has filed an IPO.	18-09-18	CI
InnoTherapy, Inc. has withdrawn its IPO.	18-09-17	CI
InnoTherapy, Inc. has filed an IPO.	17-06-21	CI

Chart SCL Science Inc.

Duration

Period

More charts

Company Profile

SCL Science Inc, formerly InnoTherapy Inc, is a Korea-based company principally engaged in the research, development, manufacture, export and sale of medical hemostatic agents. The main developed products include medical hemostats and sealants with biomimetic technology. In addition, the Company is engaged in the bio-logistics business.

Sector

Pharmaceuticals

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
SCL SCIENCE INC.	-2.25%	45.6M
CSL LIMITED	-4.24%	86.85B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.16B
BIOGEN INC.	-16.48%	31.28B
UCB	+57.86%	25.27B
BIOMARIN PHARMACEUTICAL INC.	-13.58%	15.33B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+6.89%	8.83B
INNOVENT BIOLOGICS, INC.	-10.53%	7.94B